Emergency Department–Initiated Buprenorphine for Opioid Use Disorder
JAMA · 17.03.2026 · 335 (11) · 948
DOI: 10.1001/jama.2025.27019 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift JAMA, erschienen am 17.03.2026. Verfasst von Gail D'Onofrio und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut. Hauptthemen laut MEDLINE: Buprenorphine, Emergency Room Visits, Narcotic Antagonists, Opiate Substitution Treatment. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Importance Extended-release injectable buprenorphine may expand the reach of initiating medications for opioid use disorder in high-risk and hard-to-reach individuals who visit the emergency department (ED) and can be administered in low levels of withdrawal.
Objective
To compare the effect of ED-initiated 7-day extended-release injectable buprenorphine vs sublingual buprenorphine on treatment engagement at 7 days. Design, Setting, and Participants Multicenter randomized clinical trial enrolling adult patients presenting to the ED with untreated opioid use disorder and a Clinical Opiate Withdrawal Scale (COWS) score of 4 or higher across 29 EDs in the US from July 12, 2020, to August 21, 2024. Final follow-up was completed on October 24, 2024.
Interventions
Patients were randomized to receive a 24-mg injection of extended-release buprenorphine (equivalent to 16 mg/d) or sublingual buprenorphine, which included either self-administration instructions if the COWS score was less than 8 or administration of 8 mg of sublingual buprenorphine in the ED if the COWS score was 8 or higher. All sublingual buprenorphine group patients received a 7-day prescription for 16 mg/d. Both groups were provided referral for ongoing medication with a scheduled appointment within 7 days. Main Outcomes and Measures Engagement in opioid use disorder treatment on day 7 was the primary outcome. Secondary outcomes included engagement at 30 days, precipitated withdrawal and overdose events, craving scores, days of illicit opioid use, and patient satisfaction with treatment.
Results
Among 2000 patients randomized, 6 who were enrolled twice were excluded, resulting in 991 in the extended-release group and 1003 in the sublingual group. The median age was 37 (IQR, 30-47) years, 68% were male, 31% had an initial COWS score of 4 to 7, and 76% tested positive for fentanyl. The adjusted proportion of engagement in opioid use disorder treatment at 7 days was 40.5% with extended-release buprenorphine vs 38.5% with sublingual buprenorphine (adjusted difference, 1.6%; 95% CI, −2.8% to 6.0%). Engagement at 30 days was similar, with adjusted proportions of 43.8% with extended-release buprenorphine vs 44.9% with sublingual buprenorphine (adjusted difference, −1.5%; 95% CI, −6.2% to 3.2%). Precipitated withdrawal was rare: 6 (0.6%) with extended-release buprenorphine and 8 (0.8%) with sublingual buprenorphine. Overdose events within 30 days occurred in 18 participants (2.3%) in each group. Patients receiving extended-release buprenorphine reported lower mean craving scores at 7 days vs those receiving sublingual buprenorphine (scale, 0-100; mean score, 26.5 vs 30.2, respectively; adjusted mean difference, −3.85; 95% CI, −7.08 to −0.63), fewer days of illicit opioid use in the past 7 days (adjusted ratio of means, 0.77; 95% CI, 0.68-0.95), and better treatment satisfaction scores (scale, 1-5; adjusted mean difference, 0.13; 95% CI, 0.01-0.25). Conclusions and Relevance No difference was detected in opioid use disorder treatment engagement on day 7 between the 7-day extended-release and sublingual buprenorphine groups. Both buprenorphine formulations were well tolerated; precipitated withdrawal was rare despite a high prevalence of fentanyl. Trial Registration ClinicalTrials.gov Identifier: NCT04225598
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut.
- Department of Medicine, Yale School of Medicine, New Haven, Connecticut.
- Department of Chronic Disease Epidemiology, School of Public Health, Yale University, New Haven, Connecticut.
- Department of Emergency Medicine and Division of Addiction Medicine, Highland General Hospital-Alameda Health System, Oakland, California.
- Department of Emergency Medicine, University of California, San Francisco.
- Department of Emergency Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Förderung
- NIDA NIH HHS
Zitieren
APA
D'Onofrio, G., Herring, A. A., Hawk, K. F., Perrone, J., Cowan, E., McCormack, R. P., Dziura, J., Matthews, A. G., Pantalon, M. V., Owens, P., Martel, S., Coupet, E., Lofwall, M. R., Walsh, S. L., Edelman, E. J., Carpenter, J. E., Strout, T. D., Baumann, M. R., Anderson, E., …, & ED INNOVATION Investigators (2026). Emergency Department–Initiated Buprenorphine for Opioid Use Disorder. JAMA, 335(11), 948. https://doi.org/10.1001/jama.2025.27019
Vancouver
D'Onofrio G, Herring AA, Hawk KF, Perrone J, Cowan E, McCormack RP, et al. Emergency Department–Initiated Buprenorphine for Opioid Use Disorder. JAMA. 2026;335(11):948. doi:10.1001/jama.2025.27019
BibTeX
@article{DOnofrio2026,
author = {D'Onofrio, Gail and Herring, Andrew A and Hawk, Kathryn F and Perrone, Jeanmarie and Cowan, Ethan and McCormack, Ryan P and Dziura, James and Matthews, Abigail G and Pantalon, Michael V and Owens, Patricia and Martel, Shara and Coupet, Edouard and Lofwall, Michele R and Walsh, Sharon L and Edelman, E Jennifer and Carpenter, Joseph E and Strout, Tania D and Baumann, Michael R and Anderson, Erik and Barrett, Tyler W and Dorey, Alyrene and Taillac, Peter and Cochran, Gerald and Crandall, Cameron S and Wilson, Jason and Manteuffel, Jacob and Cole, Jon B and Whiteside, Lauren K and Jones, Christopher and Samuels, Elizabeth and Huntley, Kristen and Fiellin, David A and ED INNOVATION Investigators, ED INNOVATION Investigators},
title = {Emergency Department–Initiated Buprenorphine for Opioid Use Disorder},
journal = {JAMA},
year = {2026},
volume = {335},
number = {11},
pages = {948},
doi = {10.1001/jama.2025.27019}
}
EUVIMED